Malignant mesothelioma ( MM ) is a solid tumor largely unresponsive to conventional therapies. Immunological gene therapy shows promise in murine models and human clinical trials; however, the role of surgery in combination with gene therapy has not been widely studied. The aim of this study was to determine if debulking surgery improved the effectiveness of gene therapy in a murine MM model. Mice were subcutaneously inoculated with the MM cell line, AC29, at two different sites, 4 days apart, to allow a surgical and distal site tumor to develop. Once tumors were established, the surgical site tumor was debulked and vaccination of syngeneic tumor transfectants encoding genes for IL -4, IL -2, GM -CSF, B7 -1 or allogeneic MHC molecules commenced at a site away from both tumors, and tumor growth was measured. Neither debulking surgery nor gene therapy alone delayed tumor growth. However, there was a clear delay of tumor growth when debulking surgery was combined with vaccination of tumor transfectants expressing B7 -1 or high levels of GM -CSF. Combinations of these two transfectants did not lead to a synergistic effect. This study demonstrates that debulking surgery can augment the immunostimulatory effects of immunological gene therapy and can delay tumor growth. This has implications for the future design of human gene therapy trials for solid tumors such as MM.
S olid tumors that cannot be completely resected surgically often have a poor prognosis, with at best modest improvement in survival seen with further surgery, chemotherapy or radiotherapy. One such tumor is malignant mesothelioma ( MM ), an aggressive tumor of serosal surfaces, pleura and peritoneum, which is largely unresponsive to conventional treatment modalities and has a median survival from diagnosis of approximately 8.5 months.
1 Some physicians advocate surgery as a viable treatment option for MM to control local disease and reduce the risk of recurrence; however, survival in these patients is not significantly prolonged. In addition, there is significant morbidity and mortality associated with these procedures and recurrence of MM, either locally or distally, is common. 2, 3 Recent studies have focused on combining surgery for local control of MM (extrapulmonary pneumonectomy or decortication ) with adjuvant chemotherapy and/or radiotherapy to control distal disease with minimal success. 3, 4 More recent treatment strategies for solid tumors such as MM, particularly gene therapy and immunotherapy, have shown some promise in both human 5, 6 and murine studies. Several cytokines, including IL -2, 7, 8 GM -CSF, 9 B7 -1, 10, 11 IL -12, 12 IFN -, 13, 14 and IFN - 15 have demonstrated significant antitumor effects. However, the delivery of these cytokines has been problematic, which has limited the use of these cytokines in clinical practice, hence the need for gene therapy approaches that aim to improve cytokine delivery.
Tumors have been shown to be immunosuppressive 16, 17 and early studies demonstrated that excision of a primary tumor may augment any resistance that develops to tumor challenge in hosts bearing a progressive tumor, a phenomenon often referred to as concomitant immunity. 18, 19 We therefore hypothesized that debulking (cytoreductive ) surgery, if combined with immunological gene therapy using tumor transfectants containing immunologically active molecules (including cytokines and molecules involved in antigen presentation and T cell stimulation) , would generate a more effective systemic antitumor response than either treatment alone. We performed this study using a welldescribed murine model of MM that demonstrates all the histological and pathological features of the human disease and like most solid tumors is nonimmunogenic. We used a parental MM cell line (AC29 ) and tumor transfectants expressing different immunologically active molecules. In this model, we studied established tumor with a surgical / primary site tumor and a distal site tumor, thus mimicking the typical clinical situation of cancer in humans, that is of primary /local tumor accessible to surgery, plus a distal tumor that is not removed at surgery.
In this study, we showed that neither surgical tumor debulking alone nor immunological gene therapy at a remote site away from tumor was effective at delaying tumor growth. However, the combination of debulking surgery followed by immunological gene therapy led to the generation of a systemic immune response as shown by delayed tumor growth at all tumor sites and that the two most effective agents were transfectants expressing either GM -CSF or B7 -1.
MATERIALS AND METHODS

Mice
All mice used were specific pathogen free CBA /CAH females aged between 6 and 8 weeks obtained from the Animal Resource Centre ( Murdoch, Western Australia ) . The study was approved by the Animal Ethics Committee of the University of Western Australia and mice were maintained as per the National Health and Medical Research Council of Australia Guidelines for Animal Research. All experiments contained at least five mice in each experimental group and were repeated at least three times.
Cell lines
The murine MM cell line, AC29, derived from tumors induced by crocidolite asbestos injected intraperitoneally into a CBA mouse, has been described previously. 20 Cells were cultured in ''R10'' medium that consisted of RPMI-1640 (Gibco /BRL, Grand Island, NY ) supplemented with 10% fetal calf serum (FCS ) ( CSL, Melbourne, Australia ) , gentamicin 48 mg / L (Sigma Chemical, St. Louis, MO ) , benzylpenicillin 60 mg / L (CSL ), 2 g/L sodium hydrogen carbonate (BDH, Victoria, Australia ), 20 mM N -2-hydro -2 -ethylpiperazine -N -2-ethane sulfonic acid ( HEPES ) ( Gibco /BRL ), and 2-mercaptoethanol (Sigma) . All cell lines used were tested regularly for mycoplasma contamination and were consistently found to be mycoplasma negative.
DNA constructs and transfection procedures
The parental tumor cell line, AC29, was transfected after passage number 60 and all transfectants were grown in the relevant selection media with either the neomycin analogue, G418 /geneticin (Gibco/ BRL ) at a concentration of 400 g /mL, or Hygromycin B ( Boehringer Mannheim, Amsterdam, The Netherlands ) at a concentration of 200 g/ mL.
Tumor transfectants AC29 cells transfected with genes coding for IL -4, GM -CSF, B7 -1, allogeneic MHC, and IL -2 were selected for these experiments because they have been shown to be immunogenic, i.e., they all fail to grow or grow slowly compared to the parental AC29 cell line and they all induce some protection against rechallenge. The growth rate of the different tumor transfectants in syngeneic mice is summarized in Table 1 .
The murine IL -4 gene in the expression vector, BCMGneo, was kindly supplied by the Basel Institute for Immunology ( Basel, Switzerland ). Stable transfectant clones were generated using the cationic lipid, DOTAP ( Boehringer Mannheim ), followed by selection with Hygromycin B ( Boehringer Mannheim ) and two rounds of limiting dilution cloning. Cloned transfectants were maintained in continuous culture for less than 3 months.
The human beta actin GM -CSF plasmid ( pBAprneoGM -CSF ) was constructed as follows. The GM -CSF insert was excised from pGM3.2 ( from G. Begley, Walter and Eliza Hall Institute, Melbourne, Australia ) by digestion with Hinf -Bsu361 ( 477 bp) . The fragment was blunt ended with Klenow and ligated into EcoRV site of kCMV enhancer ( human CMV enhancer /promoter ) . The pBApr-neoGM-CSF plasmid was constructed by excising SalI and BamHI fragment from kCMV-GM -CSF and subcloned into pApr MUKHERJEE, NELSON, LOH, ET AL: IMMUNE ANTI-TUMOR EFFECTS OF GM-CSF AND B7-1 ( human beta actin promoter ). The transfection procedure was as described above for the IL-4 transfection. Selection of clones occurred using the neomycin analogue, geneticin / G418 (Gibco/ BRL ) .
The transfection procedures for B7 -1, allogeneic class I MHC, and IL -2 have all been previously described. 7, 10, 11, 21 As control transfectants, tumor cells were transfected with the phb -Apr-neo vector alone and maintained as described above.
In vitro production / expression of cytokines from the tumor cytokine transfectants Cytokine production by tumor transfectants was measured by seeding 1Â10 5 cells in 1 mL of R5, leaving them for 48 hours at 378C and 5% CO 2 and collecting the supernatant, which was then screened by ELISA (Pharmingen, San Diego, CA ) . Surface molecule expression of B7 -1 and allogeneic molecule expression was assessed by flow cytometry, using antimurine B7 -1 (Pharmingen ) and anti -H -2D d (American Type Culture Collection, Manassas, VA, HB102 ) followed by FITC -conjugated F (ab ) 2 sheep antimouse immunoglobulin (Silenus, Hawthorn, Australia ) . Antibody staining and flow cytometry (Becton Dickinson, Mountain View, CA ) were as described previously. 21 A list of all tumor transfectants and their associated expression levels of cytokines is summarized in Table 1 .
Tumor inoculation
Mice were injected with 1Â10 6 AC29 cells subcutaneously ( s.c. ) on the right flank (''surgical site'' tumor ) on day À 11. To create a ''distal site,'' 5Â10 5 AC29 cells were then injected s.c. on the left flank 4 days later (day À 7) . Tumor diameters were measured with calipers at different time points and expressed as tumor volume in cubic millimeters as calculated by the formula: tumor volume (mm 3 ) = ( shortest tumor dimension in millimeter ) 2 Âlarger tumor dimension in millimeter.
Debulking surgery
Debulking of the surgical site tumor was undertaken 11 days after inoculation ( arbitrarily defined as day 0 ) when the surgical site tumor volume measured between 8 and 25 mm 3 . Mice were anaesthetized and all macroscopically visible tumors were removed via a 1-to 2 -cm incision. The wound was closed using titanium sutures (Ethicon Endo-surgery, Cincinnati, OH ) . For all experiments, there was no significant difference in tumor volumes between groups before debulking as assessed by ANOVA (P=.34).
Vaccination using single tumor transfectants
Vaccination using single tumor transfectants was undertaken on days 3, 6, 10, 12, and 17 after debulking; 5Â10 5 cells of the relevant single tumor transfectant were injected s.c. at multiple sites well removed from both the debulked surgical tumor site and the distal tumor site. Mice were sacrificed on day 18 after debulking and their tumors were frozen after being embedded in OCT (Sakura Finetechnical, Tokyo, Japan ).
Vaccination of combination tumor transfectants was undertaken on days 2, 6, 9, 12, and 15 at multiple sites well removed from tumor deposits, as follows: 5Â10 5 cells each of either AC29 -GM -CSF 1.6 with AC29 -B7 -1, or AC29 -GM -CSF 1.6 with AC29 -B7 -1 and AC29 -IL-4. Mice were sacrificed when the tumor volume of one of any site exceeded 1000 mm 3 . In another series of parallel experiments, mice did not have their surgical site tumors debulked, the vaccination regime being otherwise identical to that described above for debulked tumors. Mice were vaccinated with 5Â10 5 cells s.c. of AC29 -GM -CSF 1.6, AC29 -B7 -1 or a combination of 5Â10 5 cells of both tumor transfectants and assessment undertaken as above.
Immunohistochemistry
Frozen sections of tumor were obtained, fixed in cold absolute alcohol, washed, and endogenous peroxidase blocked using 1% hydrogen peroxide. Primary antibodies directed against murine CD4 and CD8 T cells (clones MT310 and MT25, respectively; Dako, Carpinteria, CA ) , MHC Class II molecules (TIB -120 from P. Holt, Institute of Child Health Research, Perth, Australia ), macrophages ( F4 /80; 22 ) , and CD11c ( N418, which is expressed on dendritic cells; 23 ) ( the latter two antibodies were kindly supplied by A. McWilliam, University of Western Australia, Perth, Australia ) , were applied for 45 minutes at room temperature, and sequentially linked to the secondary biotinylated antibody ( sheep antimouse Ig; Jackson ImmunoResearch Laboratories, West Grove, PA ) , and streptavidin -horseradish peroxidase (Dako ) . Staining was visualized by precipitating DAB (3,3 diaminobenzidine; Sigma ) and counterstaining with haematoxylin. Sections were mounted in Immunomount ( Shandon, Pittsburgh, PA ) .
Statistical analysis
The primary outcome variable of the statistical analyses was the tumor volume in each mouse measured at each time point. The principal explanatory variables were the different treatment groups. Tumor volume was analyzed as continuous. Treatment groups were analyzed as categorical variables.
At each time point, either one -way ANOVA or a twosampled t test was used to compare mean tumor volume within each treatment group depending on the number of groups being compared. 24 Initial ANOVA analyses indicated that, in the debulking surgery experimental series, the control group that did not undergo debulking had dramatically larger mean tumor volumes at all time points than the other groups. Therefore, all subsequent analyses of the debulking experiments excluded this control group from the analysis. This allowed ANOVA analysis comparing different groups of mice that were debulked and vaccinated with different treatments.
Minitab for Windows v12.1 (Minitab ) and S -Plus v4.5 ( Mathsoft ) were used to manage and analyze data. Statistical significance was defined at the standard 5% level.
RESULTS
Effect of debulking surgery alone
Palpable surgical site tumors ( size range of 8 to 25 mm 3 ) were debulked 11 days after inoculation ( termed day 0) ; however, even though all macroscopically visible tumors were excised at the time of surgery, tumor regrowth at this site inevitably occurred. In some instances, regrowth was detectable as early as day 3 after surgery ( Fig 1A ) . Furthermore, the rate of regrowth after debulking surgery was not different to that seen in nonsurgically treated mice. Similarly, debulking of the surgical site tumor did not produce any delay in growth of the distal site tumor compared to tumor growth in mice that did not have their surgical site tumor debulked (Fig 1B ) . These data do not suggest any evidence of augmentation of ''concomitant immunity'' after tumor excision in this tumor model.
Effect of debulking surgery plus single tumor transfectant vaccination
Although debulking surgery alone had no effect on distal tumor growth, we considered it possible that the surgical procedure may have induced a weak antitumor response that was unable to slow tumor growth. In an effort to unmask any such effect, we set out to determine whether immunological gene therapy after debulking surgery could lead to delayed tumor growth. Mice were debulked as above and then the vaccination protocol commenced 3 days later, at a remote site away from both tumors, using a number of immunogenic tumor transfectants. Vaccination with two of the tumor transfectants, AC29 -GM -CSF 1.6 and AC29 -B7 -1, consistently produced a delay in surgical site tumor regrowth, in comparison to other treatment groups. This delay became evident at day 12 ( F 8,38 = 2.73, P= .05 ) and increased by day 17 (F 8,42 =4.85, P=.02 ) (Fig 2A ) .
Distal site tumor growth after debulking surgery and vaccination with tumor transfectants was also significantly different between groups at day 12 ( F 8,44 = 2.54, P=.02) and this difference was even more pronounced by day 17 ( F 8,39 = 3.14, P= .007 ). Maximal retardation of growth was seen in groups vaccinated with AC29 -IL -2, AC29 -GM -CSF 1.6, AC29 -B7 -1, and AC29 -GM -CSF 4.5 ( Fig 2B) and there appeared to be acceleration of tumor growth in the group vaccinated with AC29 -IL -4. Interestingly, in groups vaccinated with AC29 -GM -CSF 1.6 and AC29 -B7 -1, the MUKHERJEE, NELSON, LOH, ET AL: IMMUNE ANTI-TUMOR EFFECTS OF GM-CSF AND B7-1 benefit was as marked on the distal tumor site as on the surgical tumor site.
Tumor immunohistochemistry
Immunohistochemistry of both surgical and distal site tumors removed at the time of sacrifice ( day 18 ) revealed evidence of a modest T cell infiltration (CD4 and CD8 ) in groups that received AC29 -GM -CSF 1.6 and AC29 -B7 -1 vaccination (data not shown ). Importantly, these groups also showed areas of marked necrosis compared to control and other active treatment tumors ( data not shown ).
Effect of vaccination with AC29 -GM -CSF 1.6 and B7 -1 in the absence of debulking surgery
To be certain that the beneficial effects of postsurgical gene therapy with the two tumor transfectants, AC29 -B7 -1 and AC29 -GM -CSF 1.6, was related to their combination with surgery, we vaccinated mice with these tumor transfectants at a remote site from both tumors in the absence of surgical site debulking. When gene therapy using the two transfectants was performed in the absence of surgical debulking, no significant differences were seen in tumor growth between these groups and controls for surgical site ( Fig 3A ) or distal site tumors ( Fig 3B ) . Similarly, no beneficial effects were seen when the two transfectants were combined (data not shown) . These data confirm that the act of debulking was essential in the generation of the systemic antitumor response observed in Figure 2A and B.
Effect of debulking surgery in conjunction with a vaccination protocol using the two most effective tumor transfectants As postsurgical vaccination with the two single transfectants demonstrated a beneficial outcome, we reasoned that combining them could produce a synergistic effect. Therefore, we undertook our vaccination protocol giving mice five sequential s.c. injections of 5Â10 5 cells of both AC29 -GM -CSF 1.6 and AC29 -B7 -1, commencing 2 days after debulking surgery. No significant difference in tumor 6 cells of the surgical / primary site tumor were given on day À 11 on the right flank, and 5Â10 5 distal site tumor cells ( day À 7 ) on the left flank. Surgical site tumors were not debulked on day 0. Vaccination of tumor cytokine transfectants s.c. occurred on days 2, 6, 9, 12, and 15 at multiple, rotating sites removed from both tumor deposits. At each of these time points, the active treatment groups were vaccinated with 5Â10 5 cells s.c. of either AC29 -GM -CSF 1.6 or AC29 -B7 -1. Mice were followed over time and were sacrificed when the tumor volume of one of either of the tumor sites exceeded 1000 mm 3 . Each point reflects the mean tumor volume of the treatment group ( error bars not shown ) . A shows surgical site tumor growth in mice that did not undergo debulking surgery. B shows distal site tumor growth in mice that did not have their surgical site tumor debulked. These mice were also vaccinated with both AC29 -B7 -1 and AC29 -GM -CSF 1.6 simultaneously and the tumor growth rates were not significantly different to the separate treatment ( data not shown ) . Data shown are from one representative experiment of the three experiments performed. Figure 4 . Surgical and distal site tumor growth after debulking surgery and vaccination with AC29 -GM -CSF 1.6 and AC29 -B7 -1 simultaneously. A shows the surgical site tumor growth in mice that had their surgical site tumor debulked. B shows distal site tumor growth in mice that had their surgical site tumor debulked. Surgical site tumors were debulked ( day 0 ) and s.c. vaccination with combination tumor cytokine transfectants occurred on days 2, 6, 9, 12, and 15 at multiple, rotating sites removed from both tumor deposits. At each of these time points, the active treatment group was vaccinated with 5Â10 5 cells s.c. of each of AC29 -GM -CSF 1.6 and AC29 -B7 -1. Mice were followed over time and were sacrificed when the tumor volume of one of either the surgical or distal site tumors exceeded 1000 mm 3 . Each point reflects the mean tumor volume of the treatment group ( + SD error bars ) . Significance level of P < .05 at different time points is indicated by *. Data shown are from one representative experiment of the three experiments performed.
Cancer Gene Therapy, Vol 8, No 8, 2001 volume of the surgical site tumor was seen between the treatment and control groups at any time point ( Fig 4A ) . In contrast, tumor volume of the distal site tumor was lower by day 12 in the group receiving the combination vaccination regime ( T 10 = À 3.08, P= .01) and this persisted to day 21 ( T 7 = À 2.50, P=.03 ) (Fig 4B ) .
Effect of combined debulking surgery and gene therapy coding factors known to augment antigen presentation Thus far, the two transfectants that have demonstrated a potentially positive clinical outcome are those expressing GM -CSF and B7 -1. Both molecules play a critical role in antigen presentation. GM -CSF is essential for the maintenance and survival of dendritic cells (DC ) , the most potent of all professional antigen presenting cells ( APC ), while B7 -1 is a co-stimulatory molecule expressed on APC that activates T cells and generates effector /memory T cells. As IL -4, in association with GM -CSF, has been shown in both human and murine in vitro studies to be involved in DC survival and maturation, 25, 26 we reasoned that the addition of the AC29 -IL-4 transfectant might augment the antitumor response seen in Figure 2 . Neither surgical site tumor volume nor distal site tumor volume was significantly different between treatment groups after debulking surgery (Fig 5A  and B ) .
DISCUSSION
It is now known, contrary to previously held views, that solid tumors are not hidden from the host immune system. However, the antitumor response is weak 27 and in most instances unable to overcome multiple tumor defenses. In addition, tumors are immunosuppressive; 28 therefore, excising them may improve host antitumor responses. This is observed in some, but not all, animal models ( concomitant immunity ). However, this is not a feature of surgery for human cancer as debulking alone rarely prolongs survival when matched patient groups are examined suggesting that concomitant immunity post -tumor excision is not sufficient on its own to boost antitumor immune responses. Immunological gene therapy provides a powerful tool to enhance antitumor immunity in animals and is being tested in clinical trials. 6, 29 Although debulking surgery alone may not be enough in itself to unmask a strong antitumor immune response, the addition of immunological gene therapy to further boost these responses is both logical and more likely to lead to an effective systemic immune response. In this study, we addressed the hypothesis that a combination of these two approaches would be more effective than either treatment alone, and show that this is indeed the case for both local and distal tumors. We used a model of established, solid tumor that parallels the clinical situation, rather than tumor protection experiments that are easier to perform but less clinically relevant.
Why did debulking surgery alone fail to delay tumor growth?
In this study, we showed that debulking of a solid tumor inevitably resulted in tumor regrowth at the surgical site, an observation that parallels the common complication of local recurrence after surgery in many clinical situations, including extrapleural pneumonectomy in MM. 30 While we have not examined the underlying mechanisms that contribute to post surgical regrowth, it is possible that the act of surgery itself may contribute to tumor re -emergence at the wound site. Despite excision of all macroscopically visible tumors at the time of surgical debulking, it is still probable that a few tumor cells were left within the wound site. Instead of being phagocytosed and destroyed by infiltrating immune cells recruited to the surgical site during a transient local inflammatory response initiated immediately after surgery, it is possible that wound healing factors may have provided a tumorigenic microenvironment. For example, the wound healing factors, transforming growth factor-( TGF -) and platelet -derived growth factor ( PDGF ), which are known to accelerate the growth of many solid tumors including MM, 17, 31 are likely to be present at the surgical site.
In our model, we were unable to find any evidence of a phenomenon described as concomitant immunity 18 in which surgical debulking is reported to result in a slower growth Figure 5 . Surgical and distal site tumor growth after debulking surgery and vaccination with AC29 -GM -CSF 1.6, AC29 -B7 -1, and AC29 -IL -4 simultaneously. Surgical site tumors were debulked ( day 0 ) and s.c. vaccination with combination tumor cytokine transfectants occurred on days 3, 7, 10, 12, and 15 at multiple, rotating sites removed from both tumor deposits. At each of these time points, the active treatment group was vaccinated with 5Â10 5 cells s.c. of each of AC29 -GM -CSF 1.6, AC29 -B7 -1, and AC29 -IL -4. Mice were followed over time and were sacrificed when the tumor volume of one of either the surgical or distal site tumors exceeded 1000 mm MUKHERJEE, NELSON, LOH, ET AL: IMMUNE ANTI-TUMOR EFFECTS OF GM-CSF AND B7-1 rate of distal, or metastatic, tumor. One possible explanation is that debulking surgery occurred at the earliest possible time point when the tumor was palpable (11 days after initial tumor inoculation ); therefore, the tumor burden may not have achieved a threshold size sufficient to alter host immune responsiveness. 32 Thus, debulking a small tumor may be insufficient to influence tumor growth of the distal site tumor. Another possible explanation is that concomitant immunity is not a feature of this tumor.
Why does debulking surgery delay tumor growth when combined with vaccination using GM -CSF or B7 -1 tumor transfectants?
In this study, we showed that it is possible to generate a systemic antitumor response against a solid, nonimmunogenic, murine tumor when debulking surgery is combined with immunological gene therapy, despite minimal response when either of these treatments is used alone. Importantly, the tumor transfectants that were most effective at generating this response were those that secreted a high concentration of GM -CSF or expressed the T lymphocyte costimulatory molecule, B7 -1.
GM -CSF in other tumor models, including malignant melanoma and malignant glioma, has been shown to generate potent, specific, persistent antitumor immunity. 33 A pilot study of GM -CSF in MM given intratumorally produced local necrosis with an intense lymphocytic infiltration in biopsy samples in a small proportion of patients correlating with transient tumor regression. 9 We found marked areas of necrosis within tumors taken from mice treated with surgical debulking and the GM -CSF transfectant, compared to control tumors, implying that an active antitumoral process did occur. However, only a modest T cell infiltration was seen.
We have not addressed the mechanisms involved in generating this response and speculate that the cells involved are professional APC such as DC or macrophages. To address the specific mechanisms involved in mediating this response, it would be necessary to follow immune responses to known tumor antigens occurring within the lymphoid compartment in future studies. However, for human and murine MM and many other solid, non-immunogenic tumors, specific tumor antigens have been difficult to identify; therefore, to address mechanisms, surrogate tumor antigens could be used, and we are currently undertaking these studies. 34, 35 Nonetheless, the caveat of these types of studies is that transfection of nominal tumor antigens may have the potential to alter the immunogenicity of the parental tumor cell line itself, as well as cytokine and other transfectants.
Previous studies of other tumors have shown that gene therapy/ immunotherapy using GM -CSF leads to an accumulation of DC at the site of tumor formation implying that GM -CSF leads to improved antigen presentation. 36 It is known that in MM, as with many other solid tumors, the most prominent infiltrating leukocyte is the macrophage that may constitute up to 50% of the tumor mass. These macrophages are predominantly of the MHC class II negative, unactivated phenotype 10 and it is possible that they become activated after exposure to large amounts of GM -CSF. It is currently believed that the generation of effector cells after T cell activation requires antigen to be presented in the context of a MHC molecule and a second costimulatory signal. B7 -1 can provide this costimulatory signal by interacting with CD28 or CTLA -4 on the T cell surface.
37 B7 -1 may also mediate direct recognition and killing of tumor cells by natural killer cells. 38 In MM models, B7 -1 transfection in MM cell lines led to more effective protective immunity via the induction of specific anti -MM tumor cell reactivity.
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In this study, we saw retardation of tumor growth in both surgical site and distal tumors when debulking was combined with tumors transfected with B7 -1. Histological examination of tumors revealed marked areas of necrosis, as well as a minor T cell infiltrate, that was equivalent to those seen when the GM -CSF transfectant was used, implying similar immune responses and underlying mechanisms.
The other transfectants IL -2, allogeneic MHC class I, and the low expressing GM -CSF transfectant were unable to generate delayed tumor growth at both tumor sites after debulking despite being immunogenic in syngeneic mice. This may be because of an inability to overcome the immunosuppressive molecules secreted around the surgical site tumor. IL-4 was found to be particularly detrimental when used as a single vaccine or in combination with immunologically effective molecules. The reasons for this phenomenon are unknown but may be due to a skewing of the immune response to Th2 -like responses.
It is intriguing that the debulked tumor consistently recurred locally despite generation of an antitumor response that was able to delay tumor growth temporarily while the vaccination regime continued. Human MM studies that have combined surgery, radiotherapy and /or chemotherapy have shown that the major site of recurrence of tumor after intensive treatment is within the hemithorax, with local recurrence rates of between 40% and 80%. 39, 40 Our study utilizing immunological gene therapy confirms in a murine model of MM that control of local and metastatic disease is possible but is dependent on continued vaccination.
Why was vaccination with GM -CSF or B7 -1 transfectants alone a failure in the absence of debulking surgery?
Single vaccination with each of the tumor transfectants, including the high GM -CSF producing cell line and the B7 -1 expressing tumor did not lead to any beneficial outcome. This implies that the use of single tumor transfectant vaccination in established tumors is unable to overcome local tumor defense mechanisms, in the absence of debulking surgery. Our results suggest that the physical act of debulking surgery was of primary importance in enabling the systemic immune response to effectively delay growth in both surgical and distal site tumors after tumor transfectant vaccination. Surgery may act to disrupt these tumor defense mechanisms initially, or may encourage inflammation that is believed to be critical in the generation of a ''danger'' signal for the immune system that encourages recruitment of immune effector cells. 41 Why did combined vaccination with these transfectants not improve outcome when used with debulking surgery?
Combining tumor cytokine transfectants did not lead to an improved outcome implying that each cytokine was acting independently. These factors may even inhibit each other in this situation. Another explanation may be that the increased dose of tumor cells that had to be injected to study combined effects actually overwhelmed the antitumor immune response and negated any effect that may have been observed due to the higher dose of cytokines available to the immune system. An alternative way to perform the experiment may have involved decreasing the number of cells for each transfectant; however, the cytokine expression of each transfectant would have been reduced accordingly. Thus, single tumor transfectant vaccination appears to be more effective than combination tumor transfectant vaccination.
Importantly, a significant delay was still evident at the distal tumor site demonstrating that the surgical site tumor growth was unrestrained, possibly due to the presence of wound healing growth factors, which cannot be overcome when the tumor transfectants are combined. One possible explanation for our observations is that debulking a surgical site tumor may reduce inhibitory effects ( via the release of tumor-associated soluble products that enter the systemic system ) on distal site tumors, allowing gene therapy to be more effective. Therefore, we propose that debulking surgery and subsequent gene therapy leads to increased control of distal, non-debulked tumors.
This study is clinically relevant. The murine AC29 cell line mimics its human counterpart and like most solid tumors is non-immunogenic. The observation that debulking surgery followed by vaccination of tumor transfectants expressing B7 -1 or high levels of GM -CSF delays tumor growth is an important observation for a number of reasons. Firstly, there are few non -immunogenic tumors, as opposed to immunogenic tumors such as malignant melanoma, that demonstrate any evidence of an effective antitumor response after specific interventions. In addition, our studies were performed on established tumor rather than being protection studies. It is very difficult to eradicate established, nonimmunogenic tumors; therefore, our findings are relevant and important. The fact that we were able to generate a systemic immune response using this model, as shown by delayed tumor growth at the surgical and distal sites of tumor, strongly suggests that clinical trials that use surgery followed by adjuvant gene therapy may yield encouraging results. We believe that these studies are essential and may lead to the use of surgery in combination with immunological gene therapy for solid tumors.
Additionally, in our study, all tumor transfectants containing immunologically active molecules did not produce delayed growth, but it was the transfectants expressing B7 -1 or high levels of GM -CSF that led to the response. This suggests that there are critical immunological molecules that must be provided at the correct concentration and time point for a response to be seen. We also demonstrated that combinations of these two transfectants did not lead to a synergistic effect that suggests that ''more is not necessarily better'' and that the interplay of cytokines is a complex one. Finally and most importantly, this study demonstrates that the act of debulking surgery was essential in mediating the delayed tumor growth after tumor transfectant vaccination. Surgery is the prime treatment option for the majority of solid tumors; therefore, if we can combine it successfully with gene therapy and initially delay tumor growth, then perhaps with optimization of the treatment schedule and better understanding of the mechanisms that mediate the response, we could effect tumor regression of non -immunogenic tumors. This has rarely been achieved so far for non -immunogenic tumors that comprise the majority of solid tumors.
In this study, the tumor transfectants used did not require irradiation because they either fail to grow, or grow slowly in vivo; however, for human tumor vaccination gene therapy, all samples would need to be irradiated to reduce the risk of tumor developing at the site of inoculation. Alternatively, viral vectors coding for GM -CSF or B7 -1 may be a viable option. Further work needs to be undertaken to address the specific mechanisms involved in this antitumor response and to elucidate the role of surgery on the immune system.
